Tags |
|
|
Links |
|
|
Advice Pool - Zelnorm Recalled by FDA, Linked to Heart Problems and Stroke
At The Law Offices of Michael A. DeMayo, L.L.P., we work tirelessly to keep a pulse on the most recent news and information that may affect our
According to USFDA, a combination product is one composed of any combination of a drug and device; biological product and device; drug and biological product
clients. One area that we are particularly attentive to is the area of dangerous drugs. Most recently our focus has been on Zelnorm.
On March 3
On March 3
; or drug, device, and biological product and fixed dose combination would include two or more combinations of drug.
Examples of combination products may in
Examples of combination products may in
, 2007 the FDA issued an advisory informing the public that Novartis is complying with an FDA request to suspend marketing of Zelnorm. This requ
lude drug-coated devices, drugs packaged with delivery devices in medical kits, and drugs and devices packaged separately but intended to be used together.
est was made as a result of the drug being linked to an increased risk of heart attack, stroke and unstable angina.
Just a few days later, on A
Just a few days later, on A
here is enormous increase in the number of combination products entering the market in the recent years. Combination products have proven advantages but fixe
ril 2, 2007 the FDA took stronger action and removed Zelnorm from the market subsequent to analyzing the results of an extensive study of the dr
d dose combinations are still in the process of convincing regulatory authority on their advantages over the single ingredient formulations.
Combination pro
Combination pro
g’s performance. The analysis included data gleaned from more than 18,000 patients, most of whom were treated with Zelnorm but some of whom rece
ucts have become life saving products for the pharmaceutical companies who doesn’t have many innovative molecules in their product pipeline and have been inc
ived a placebo. The conclusion was that the benefits of the drug do not outweigh the risks. Those risks include serious cardiovascular adverse e
easingly used in the product life cycle management. Even the companies having product patents are trying to extend their product life cycle through the combi
ents such as heart attacks and strokes. Zelnorm has also been linked to severe cases of diarrhea, ischemic colitis and potentially death.
Zelno
Zelno
nation products and maximize the revenues. But the companies involved in this practice are overlooking that they are burdening the patients both economically
m was initially marketed in the U.S. from August of 2002 through March 2004. During that period the FDA adverse reporting system did receive re
and physically. They need to rightly judge the benefits of the combination products and they have to even look at the risks involved when combining the produ
ports of patients who experienced serious adverse events. These reports included 21 that presented with serious consequences for diarrhea, 20 pa
ts. Some of the combination products were well accepted by physicians while others suffered. Companies involved in development of combination products are fi
ients that were diagnosed with ischemic colitis and 3 patients diagnosed with other types of intestinal ischemia. In some patients, these advers
ding difficulty in defining their combination products and facing various challenges from selecting a combination to marketing it.
Following aspects would a
Following aspects would a
events have led to hospitalization, surgery and even death.
Since being approved by the FDA in 2002, Zelnorm, manufactured by Swiss drug maker
Since being approved by the FDA in 2002, Zelnorm, manufactured by Swiss drug maker
dd to the challenges in developing combination products:
Which markets to tap where the combination products can do fairly well?
Which combination prod
Which markets to tap where the combination products can do fairly well?
Which combination prod
Novartis AG, has been prescribed as a short term medication for women coping with irritable bowel syndrome. The primary symptom is constipation
cts are meaningful and rational?
Which therapeutic categories to select?
Which Combinations can address unmet needs of the patients?
Do combin
Which therapeutic categories to select?
Which Combinations can address unmet needs of the patients?
Do combin
The drug increases the movement of stools through the bowels. It does not cure irritable bowel syndrome but it has been shown to help the condi
tions increase the patient compliance?
What would be the developing cost?
How to tackle the risks encountered during combination product developmen
What would be the developing cost?
How to tackle the risks encountered during combination product developmen
ion in some regards.
Zelnorm was marketed in 55 countries and was the first drug the FDA approved for the treatment of irritable bowel syndrome
Zelnorm was marketed in 55 countries and was the first drug the FDA approved for the treatment of irritable bowel syndrome
t?
As combination products don't fit into the traditional categories of drugs, medical devices, or biological products, the USFDA is in the process of devel
As combination products don't fit into the traditional categories of drugs, medical devices, or biological products, the USFDA is in the process of devel
. Prior to being recalled it was under prescription to about 500,000 people and in 2006 alone the drug generated just under five hundred million
ping new procedures for reviewing their safety, efficacy and quality.
Professional from academic institutions, pharmaceutical industries, health care indust
Professional from academic institutions, pharmaceutical industries, health care indust
dollars in revenues for the company.
The FDA made the following announcements in its Public Health Advisory:
· Patients being treated with Zel
The FDA made the following announcements in its Public Health Advisory:
· Patients being treated with Zel
y and representatives from various regulatory agencies are working out to design the regulatory requirements for manufacture and sale of combination products
orm should contact their physician to discuss alternative treatments for their condition.
· Patients who are taking Zelnorm should seek imm
· Patients who are taking Zelnorm should seek imm
.
As there is an increasing trend of the combination products companies manufacturing such products should be able to tackle the problems involved in the de
As there is an increasing trend of the combination products companies manufacturing such products should be able to tackle the problems involved in the de
ediate medical treatment if they experience any of the following symptoms: severe chest pain, shortness of breath, dizziness, any known symptom
elopment. They need to be wiser in analyzing the market trends and the regulatory requirements.
Companies that provide selfless information through particip
Companies that provide selfless information through particip
of a heart attack or stroke.
· Physicians who prescribe Zelnorm should work with their patients to find appropriate alternative treatments
· Physicians who prescribe Zelnorm should work with their patients to find appropriate alternative treatments
tion in industry events and feedback to regulatory authorities would be able to face the challenges and will be successful in developing combination products
HTTP = HTML link (for blogs, profiles,phorums):
<a href="http://www.advicepool.org.ua/article/130872/advicepool-Zelnorm-Recalled-by-FDA-Linked-to-Heart-Problems-and-Stroke.html">Zelnorm Recalled by FDA, Linked to Heart Problems and Stroke</a>
BB link (for phorums):
[url=http://www.advicepool.org.ua/article/130872/advicepool-Zelnorm-Recalled-by-FDA-Linked-to-Heart-Problems-and-Stroke.html]Zelnorm Recalled by FDA, Linked to Heart Problems and Stroke[/url]
Related Articles:
Social Perception And Sales Management
How to Choose the Best Currency Dealer and Why
Delayed Gratification and Money (or, Marshmallows and Your Financial Health)
Bookmark it:
|